The University of Florida Research Foundation, or UFRF, has named 34 faculty members as UFRF Professors for 2017-2020, including Almut Winterstein, Ph.D., a professor and chair of pharmaceutical outcomes and policy in the College of Pharmacy. The recognition goes to faculty who have a distinguished current record of research and a strong research agenda that is likely to lead to continuing distinction in their fields.
Winterstein is recognized as an international leader in drug safety and pharmacoepidemiology. She serves as the Dr. Robert and Barbara Crisafi Chair in Pharmaceutical Outcomes and Policy and has focused her research on evaluating drug safety and effectiveness in real-world populations and on devising ways to improve medication use. Since joining the UF College of Pharmacy in 2000, Winterstein has collaborated with UF Health’s teaching hospitals on studies aimed at evaluating and improving patient safety and drug therapy outcomes. She has received funding from various federal agencies and serves as chair of the Food and Drug Administration’s Drug Safety and Risk Management Advisory Committee. In 2013, Winterstein was inducted as a fellow of the International Society of Pharmacoepidemiology. She graduated with her pharmacy degree from Friedrich Wilhelm University in Bonn, Germany, and received her doctoral degree in pharmacoepidemiology and social pharmacy from Charité, Humboldt University in Berlin.
The UFRF Professors were recommended by their college deans based on nominations from their department chairs, a personal statement and an evaluation of their recent research accomplishments as evidenced by publications in scholarly journals, external funding, honors and awards, development of intellectual property and other measures appropriate to their field of expertise. In many colleges, the selection process is conducted by a special faculty committee.
The three-year award includes a $5,000 annual salary supplement and a one-time $3,000 grant. The professorships are funded from the university’s share of royalty and licensing income on UF-generated products.